| Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body's defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects 2013 · Verum · Adults aged 18–70 with at least three common cold infections in the preceding 6 months; healthy subjects | 900 mg | 16 weeks | 81 |
| Yeast-derived β-1,3/1,6 glucan, upper respiratory tract infection and innate immunity in older adults 2017 · β-1,3/1,6 glucan (Wellmune) · Community-dwelling adults aged 50–70 years | 250 mg | 90 days | 50 |
| Novel Chewable Pleuran-Based Supplement Decreases Respiratory Tract Infections in Children: A Randomised Controlled Trial 2025 · active group · Children aged 3–18 years with a documented history of recurrent respiratory tract infections | 50 mg | 90 days | 104 |
| Beverage Containing Dispersible Yeast β-Glucan Decreases Cold/Flu Symptomatic Days After Intense Exercise: A Randomized Controlled Trial 2020 · β-glucan · Healthy adults running in the 2017 Austin Marathon | 250 mg | 13 weeks | 132 |
| Effect of Oat β-Glucan on Affective and Physical Feeling States in Healthy Adults: Evidence for Reduced Headache, Fatigue, Anxiety and Limb/Joint Pains 2021 · Test · Healthy men and non-pregnant, non-lactating women aged 18–65 years with LDL-cholesterol of 3.00–5.00 mmol/L | 3 g | 4 weeks | 104 |
| Soluble and Insoluble Yeast β-Glucan Differentially Affect Upper Respiratory Tract Infection in Marathon Runners: A Double-Blind, Randomized Placebo-Controlled Trial 2020 · soluble yeast β-glucan group · Healthy adults running in the 2017 Austin Marathon | 250 mg | 13 weeks | 76 |
| Baker's yeast beta glucan supplementation increases salivary IgA and decreases cold/flu symptomatic days after intense exercise 2013 · Soluble BG · Men and women aged 29–46 registered to run a marathon | 250 mg | 4 weeks | 74 |
| Baker's yeast beta glucan supplementation increases salivary IgA and decreases cold/flu symptomatic days after intense exercise 2013 · Insoluble BG · Men and women aged 29–46 registered to run a marathon | 250 mg | 4 weeks | 73 |
| Soluble and Insoluble Yeast β-Glucan Differentially Affect Upper Respiratory Tract Infection in Marathon Runners: A Double-Blind, Randomized Placebo-Controlled Trial 2020 · insoluble yeast β-glucan group · Healthy adults running in the 2017 Austin Marathon | 250 mg | 13 weeks | 69 |
| Effect of β-glucan on drain fluid and amount of drainage following modified radical mastectomy 2014 · Group 1 · Breast cancer patients undergoing mastectomy; age and sex range not stated | 20 mg | 10 days | 65 |
| Influence of yeast-derived 1,3/1,6 glucopolysaccharide on circulating cytokines and chemokines with respect to upper respiratory tract infections 2012 · Wellmune · Healthy university students aged 18–65 years (mean age approximately 21 years) | 250 mg | 90 days | 48 |
| The role of meal viscosity and oat β-glucan characteristics in human appetite control: a randomized crossover trial 2014 · Instant oatmeal (IO) · Healthy adults aged 18 years or older, including normal-weight, overweight and obese participants; mixed sex | 1.6 g | 1 day | 48 |
| The role of meal viscosity and oat β-glucan characteristics in human appetite control: a randomized crossover trial 2014 · Old fashioned oatmeal (SO) · Healthy adults aged 18 years or older, including normal-weight, overweight and obese participants; mixed sex | 1.6 g | 1 day | 48 |
| The role of meal viscosity and oat β-glucan characteristics in human appetite control: a randomized crossover trial 2014 · Ready-to-eat breakfast cereal (RTEC) · Healthy adults aged 18 years or older, including normal-weight, overweight and obese participants; mixed sex | 1 g | 1 day | 48 |
| Baker's yeast beta-glucan supplement reduces upper respiratory symptoms and improves mood state in stressed women 2012 · Wellmune group · Healthy women, mean age 38 ± 12 years, with moderate psychological stress | 250 mg | 12 weeks | 39 |
| Effects of oat β-glucan consumption at breakfast on ad libitum eating, appetite, glycemia, insulinemia and GLP-1 concentrations in healthy subjects 2018 · Oat β-glucan breakfast · Normal-weight adults, 22 women and 11 men, mean age 26.9 years | 4 g | 1 day | 33 |
| Effect of Food Containing Paramylon Derived from Euglena gracilis EOD-1 on Fatigue in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial 2020 · EOD-1PM group · Healthy men and women aged 20–64 years with fatigue sensation in daily life | 350 mg | 4 weeks | 33 |
| Effects of Chronic Barley Consumption on Upper Respiratory Tract Symptoms in Japanese Healthy Adults: A Randomized, Parallel-Group, Controlled Trial 2024 · barley group · Healthy Japanese adults; the study reports a median age of 46 years and does not specify an age range or a condition | 1.8 g | 8 weeks | 31 |
| Increasing oat β-glucan viscosity in a breakfast meal slows gastric emptying and reduces glycemic and insulinemic responses but has no effect on appetite, food intake, or plasma ghrelin and PYY responses in healthy humans: a randomized, placebo-controlled, crossover trial 2020 · 2gOBG · Healthy, overnight-fasted men and nonpregnant women aged 18–60 years, without diabetes, BMI 20.0–30.0 kg/m² | 3 g | 1 day | 28 |
| Increasing oat β-glucan viscosity in a breakfast meal slows gastric emptying and reduces glycemic and insulinemic responses but has no effect on appetite, food intake, or plasma ghrelin and PYY responses in healthy humans: a randomized, placebo-controlled, crossover trial 2020 · 4gOBG · Healthy, overnight-fasted men and nonpregnant women aged 18–60 years, without diabetes, BMI 20.0–30.0 kg/m² | 10 g | 1 day | 28 |
| Fibre in beverages can enhance perceived satiety 2009 · oat beta-glucan beverage · Healthy volunteers aged 18–30 years | 10.5 g | 1 day | 19 |
| Effect of a Euglena gracilis Fermentate on Immune Function in Healthy, Active Adults: A Randomized, Double-Blind, Placebo-Controlled Trial 2019 · BG group · Healthy, endurance-trained men and women aged 21–65 years | 367 mg | 90 days | 17 |
| Clinical Outcomes after Oat Beta-Glucans Dietary Treatment in Gastritis Patients 2021 · G1; high molar mass oat beta-glucan group · Adults aged 23–74 with histologically confirmed chronic antral gastritis; both sexes | 3 g | 30 days | 16 |
| Clinical Outcomes after Oat Beta-Glucans Dietary Treatment in Gastritis Patients 2021 · G2; low molar mass oat beta-glucan group · Adults aged 23–74 with histologically confirmed chronic antral gastritis; both sexes | 3 g | 30 days | 16 |
| Sugar and dietary fibre composition influence, by different hormonal response, the satiating capacity of a fruit-based and a β-glucan-enriched beverage 2012 · β-glucan-enriched beverage · 14 healthy volunteers | 3 g | 1 day | 14 |
| Effect of muesli with 4 g oat beta-glucan on postprandial blood glucose, gastric emptying and satiety in healthy subjects: a randomized crossover trial 2008 · Vanilla yoghurt with muesli containing oat beta-glucan (GER1) · 12 healthy subjects; age and sex not reported | 4 g | 1 day | 12 |
| Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study 2022 · Gr. 2 (AFO-202) · Adults aged 18–65 with mild to moderate COVID-19 requiring hospitalization | 126 mg | 30 days | 8 |
| Effects of high β-glucan barley on visceral fat obesity in Japanese individuals: A randomized, double-blind study 2017 · test group · Japanese adults with waist circumference ≥85 cm for men or ≥90 cm for women and BMI ≥24 kg/m² | 4.4 g | 12 weeks | — |
| Effects of Yeast (1,3)-(1,6)-Beta-Glucan on Severity of Upper Respiratory Tract Infections: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Subjects 2019 · yeast beta-glucan group · Generally healthy men and women with at least three upper respiratory tract infections during the previous year | 900 mg | 16 weeks | — |
| A Quality-of-Life Study in Healthy Adults Supplemented with Lentinex® Beta-Glucan of Shiitake Culinary-Medicinal Mushroom, Lentinus edodes (Agaricomycetes) 2020 · Lentinex group · Healthy adults | 1 mg | 4 weeks | — |
| β -Glucan Improves Protective Qi Status in Adults with Protective Qi Deficiency-A Randomized, Placebo-Controlled, and Double-Blinded Trial 2022 · β-glucan · Adults with protective Qi deficiency | 200 mg | 12 weeks | — |
| Effects of β-glucan and inulin consumption on postprandial appetite, energy intake and food consumption in healthy females: A randomized controlled trial 2022 · β-glucan group · Women over 18 years of age, described as healthy | 6 g | 5 weeks | — |
| Cow's milk-based beverage consumption in 1- to 4-year-olds and allergic manifestations: an RCT 2016 · CMBB · Children aged 1 to 4 years attending daycare in Brazil; generally healthy, without a stated diagnosed condition | 26.1 mg | 28 weeks | 125 |
| Beneficial effects of pleuran on asthma control and respiratory tract-infection frequency in children with perennial asthma 2025 · Active (Imunoglukan P4H®) group · Children aged 7–17 years, both sexes, with partially controlled perennial asthma and at least two respiratory infection-induced acute asthma exacerbations in the prior 12 months | 200 mg | 24 weeks | 125 |
| Effect of cooked white rice with high β-glucan barley on appetite and energy intake in healthy Japanese subjects: a randomized controlled trial 2014 · BAR (cooked white rice with β-glucan enriched barley) · Healthy Japanese women aged 30–49 years, BMI >22 and <25 kg/m² | 2.9 g | 1 day | 21 |
| Post-prandial responses to cereal products enriched with barley beta-glucan 2006 · Barley crackers (BCr) · Healthy volunteers; 10 adults, 5 male, mean age 25.4 years | 3.5 g | 1 day | 10 |
| Post-prandial responses to cereal products enriched with barley beta-glucan 2006 · Barley cookies (Bc) · Healthy volunteers; 10 adults, 5 male, mean age 25.4 years | 3.5 g | 1 day | 10 |
| Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study 2022 · Gr. 3 (AFO-202 + N-163) · Adults aged 18–65 with mild to moderate COVID-19 requiring hospitalization | 3.09 g | 30 days | 8 |
| Regular Consumption of Lipigo(®) Promotes the Reduction of Body Weight and Improves the Rebound Effect of Obese People Undergo a Comprehensive Weight Loss Program 2020 · Lipigo® group · Men and women aged 18–65 years with BMI ≥27 and <40 kg/m², participating in a weight-control program | 2.73 g | 52 weeks | — |
| An Oat β-Glucan Beverage Reduces LDL Cholesterol and Cardiovascular Disease Risk in Men and Women with Borderline High Cholesterol: A Double-Blind, Randomized, Controlled Clinical Trial 2021 · OBG · Adults with LDL cholesterol between 3.0 and 5.0 mmol/L; mean age 43.3 years; men and women | 3 g | 4 weeks | 104 |
| Physicochemical properties of oat β-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial 2010 · 3 g high-MW oat β-glucan · People with LDL cholesterol ≥3.0 and ≤5.0 mmol/L; age and sex range not specified | 3 g | 4 weeks | 86 |
| Bioactive oat β-glucan reduces LDL cholesterol in Caucasians and non-Caucasians 2011 · 3 H (3 g high-MW oat β-glucan) · Healthy men and women aged 35–70 with LDL-C of 3.0–5.0 mmol/L | 3 g | 4 weeks | 86 |
| A randomized Placebo-Controlled Clinical Trial to Evaluate the Medium-Term Effects of Oat Fibers on Human Health: The Beta-Glucan Effects on Lipid Profile, Glycemia and inTestinal Health (BELT) Study 2020 · beta-glucan supplement · Italian adults aged 20–65 with moderate hypercholesterolemia and low estimated 10-year cardiovascular risk | 3 g | 8 weeks | 83 |
| Physicochemical properties of oat β-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial 2010 · 4 g medium-MW oat β-glucan · People with LDL cholesterol ≥3.0 and ≤5.0 mmol/L; age and sex range not specified | 4 g | 4 weeks | 67 |
| Bioactive oat β-glucan reduces LDL cholesterol in Caucasians and non-Caucasians 2011 · 4 M (4 g medium-MW oat β-glucan) · Healthy men and women aged 35–70 with LDL-C of 3.0–5.0 mmol/L | 4 g | 4 weeks | 67 |
| Physicochemical properties of oat β-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial 2010 · 3 g medium-MW oat β-glucan · People with LDL cholesterol ≥3.0 and ≤5.0 mmol/L; age and sex range not specified | 3 g | 4 weeks | 64 |
| Physicochemical properties of oat β-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial 2010 · 4 g low-MW oat β-glucan · People with LDL cholesterol ≥3.0 and ≤5.0 mmol/L; age and sex range not specified | 4 g | 4 weeks | 63 |
| Bioactive oat β-glucan reduces LDL cholesterol in Caucasians and non-Caucasians 2011 · 3 M (3 g medium-MW oat β-glucan) · Healthy men and women aged 35–70 with LDL-C of 3.0–5.0 mmol/L | 3 g | 4 weeks | 63 |
| Bioactive oat β-glucan reduces LDL cholesterol in Caucasians and non-Caucasians 2011 · 4 L (4 g low-MW oat β-glucan) · Healthy men and women aged 35–70 with LDL-C of 3.0–5.0 mmol/L | 4 g | 4 weeks | 63 |
| Simultaneous intake of beta-glucan and plant stanol esters affects lipid metabolism in slightly hypercholesterolemic subjects 2007 · beta-glucan muesli · mildly hypercholesterolemic men and women | 5 g | 4 weeks | 40 |
| Concentrated oat beta-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial 2007 · Treatment · Healthy, non-smoking men and women aged 22–65 years with hypercholesterolemia (total cholesterol greater than 200 mg/dL) and at risk for cardiovascular disease | 6 g | 6 weeks | 35 |
| The effects of concentrated barley beta-glucan on blood lipids in a population of hypercholesterolaemic men and women 2007 · 3 g high molecular weight BBG · Men and women with hypercholesterolaemia/moderate dyslipidaemia; ages not reported | 3 g | 10 weeks | — |
| The effects of concentrated barley beta-glucan on blood lipids in a population of hypercholesterolaemic men and women 2007 · 5 g high molecular weight BBG · Men and women with hypercholesterolaemia/moderate dyslipidaemia; ages not reported | 5 g | 10 weeks | — |
| The effects of concentrated barley beta-glucan on blood lipids in a population of hypercholesterolaemic men and women 2007 · 3 g low molecular weight BBG · Men and women with hypercholesterolaemia/moderate dyslipidaemia; ages not reported | 3 g | 10 weeks | — |
| The effects of concentrated barley beta-glucan on blood lipids in a population of hypercholesterolaemic men and women 2007 · 5 g low molecular weight BBG · Men and women with hypercholesterolaemia/moderate dyslipidaemia; ages not reported | 5 g | 10 weeks | — |
| The consumption of bread enriched with betaglucan reduces LDL-cholesterol and improves insulin resistance in patients with type 2 diabetes 2009 · Betaglucan-enriched bread · Patients with type 2 diabetes and LDL-C greater than 3.37 mmol/l (130 mg/dl) | 3 g | 3 weeks | — |
| Simultaneous intake of beta-glucan and plant stanol esters affects lipid metabolism in slightly hypercholesterolemic subjects 2007 · combination muesli · mildly hypercholesterolemic men and women | 5 g | 4 weeks | 40 |
| Food products containing free tall oil-based phytosterols and oat beta-glucan lower serum total and LDL cholesterol in hypercholesterolemic adults 2003 · TOP/beta-glucan treatment · Adults with mild-to-moderate hypercholesterolemia | 2.8 g | 6 weeks | — |
| The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study 1991 · 28 g oatmeal · Adults with LDL-C above 4.14 mmol/L or LDL-C between 3.37 and 4.14 mmol/L with multiple risk factors | 28 g | 6 weeks | — |
| The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study 1991 · 56 g oatmeal · Adults with LDL-C above 4.14 mmol/L or LDL-C between 3.37 and 4.14 mmol/L with multiple risk factors | 56 g | 6 weeks | — |
| The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study 1991 · 84 g oatmeal · Adults with LDL-C above 4.14 mmol/L or LDL-C between 3.37 and 4.14 mmol/L with multiple risk factors | 84 g | 6 weeks | — |
| The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study 1991 · 28 g oat bran · Adults with LDL-C above 4.14 mmol/L or LDL-C between 3.37 and 4.14 mmol/L with multiple risk factors | 28 g | 6 weeks | — |
| The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study 1991 · 56 g oat bran · Adults with LDL-C above 4.14 mmol/L or LDL-C between 3.37 and 4.14 mmol/L with multiple risk factors | 56 g | 6 weeks | — |
| The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study 1991 · 84 g oat bran · Adults with LDL-C above 4.14 mmol/L or LDL-C between 3.37 and 4.14 mmol/L with multiple risk factors | 84 g | 6 weeks | — |
| Baker's yeast β-glucan supplementation increases monocytes and cytokines post-exercise: implications for infection risk? 2013 · baker's yeast BG · Recreationally active men and women | 250 mg | 10 days | 60 |
| Baker's yeast beta glucan supplementation increases salivary IgA and decreases cold/flu symptomatic days after intense exercise 2013 · BG condition (Experiment Two) · Men and women aged 18–35 who were physically active and completed strenuous cycling trials | 250 mg | 10 days | 60 |
| Yeast Beta-Glucan Supplementation Downregulates Markers of Systemic Inflammation after Heated Treadmill Exercise 2020 · YBG (yeast beta-glucan) · Recreationally active men and women aged 18–50 years without the specified diagnosed disorders | 250 mg | 13 days | 31 |
| The effects of beta-glucan rich oat bread on serum nitric oxide and vascular endothelial function in patients with hypercholesterolemia 2014 · intervention group · Adults aged 18–65 with hypercholesterolemia | 30 g | 4 weeks | 30 |
| Barley β-glucan increases fecal bile acid excretion and short chain fatty acid levels in mildly hypercholesterolemic individuals 2018 · 3 g HMW barley β-glucan · Mildly hypercholesterolemic, otherwise healthy adults; age and sex not specified | 3 g | 5 weeks | 30 |
| Barley β-glucan increases fecal bile acid excretion and short chain fatty acid levels in mildly hypercholesterolemic individuals 2018 · 5 g LMW barley β-glucan · Mildly hypercholesterolemic, otherwise healthy adults; age and sex not specified | 5 g | 5 weeks | 30 |
| Barley β-glucan increases fecal bile acid excretion and short chain fatty acid levels in mildly hypercholesterolemic individuals 2018 · 3 g LMW barley β-glucan · Mildly hypercholesterolemic, otherwise healthy adults; age and sex not specified | 3 g | 5 weeks | 30 |
| Oral Intake of Carboxymethyl-Glucan (CM-G) from Yeast (Saccharomyces uvarum) Reduces Malondialdehyde Levels in Healthy Men 2015 · CM-G-administered group · Healthy men aged 26–37 years | 50 mg | 60 days | 26 |
| A controlled study on the effect of beta-glucan-rich oat bran on serum lipids in hypercholesterolemic subjects: relation to apolipoprotein E phenotype 1992 · oat bran group · People with mild to moderate hypercholesterolemia on cholesterol-lowering diets | 10.3 g | 8 weeks | 20 |
| Effect of ß-glucan on serum levels of IL-12, hs-CRP, and clinical outcomes in multiple-trauma patients: a prospective randomized study 2018 · intervention group · Multiple-trauma patients requiring enteral nutrition for at least 10 days; age and sex not specified | 3 g | — | 20 |
| Muesli with 4 g oat beta-glucans lowers glucose and insulin responses after a bread meal in healthy subjects 2008 · Muesli with 3 g beta-glucans (series 1) · Healthy volunteers with normal body mass index | 3 g | 1 day | 19 |
| Oat beta-glucans consumed at breakfast improve glucose tolerance acutely and after a subsequent lunch - a randomized dose-response study in healthy young adults 2025 · BG2 · Healthy young adults | 2 g | 1 day | 19 |
| Oat beta-glucans consumed at breakfast improve glucose tolerance acutely and after a subsequent lunch - a randomized dose-response study in healthy young adults 2025 · BG3 · Healthy young adults | 3 g | 1 day | 19 |
| Oat beta-glucans consumed at breakfast improve glucose tolerance acutely and after a subsequent lunch - a randomized dose-response study in healthy young adults 2025 · BG4 · Healthy young adults | 4 g | 1 day | 19 |
| Oat beta-glucan reduces blood cholesterol concentration in hypercholesterolemic subjects 1994 · oat gum phase · Adult men and women with hypercholesterolemia | 5.8 g | 4 weeks | 19 |
| High molecular weight oat β-glucan enhances lipid-lowering effects of phytosterols. A randomised controlled trial 2020 · OBG · Hypercholesterolaemic individuals; age and sex not stated | 3 g | 6 weeks | 18 |
| Effect of Varying Molecular Weight of Oat β-Glucan Taken just before Eating on Postprandial Glycemic Response in Healthy Humans 2020 · MW1 · Healthy adults; 16 participants, 9 men and 7 non-pregnant women, mean age 41 years | 4 g | 1 day | 16 |
| Effect of Varying Molecular Weight of Oat β-Glucan Taken just before Eating on Postprandial Glycemic Response in Healthy Humans 2020 · MW2 · Healthy adults; 16 participants, 9 men and 7 non-pregnant women, mean age 41 years | 4 g | 1 day | 16 |
| Effect of Varying Molecular Weight of Oat β-Glucan Taken just before Eating on Postprandial Glycemic Response in Healthy Humans 2020 · MW3 · Healthy adults; 16 participants, 9 men and 7 non-pregnant women, mean age 41 years | 4 g | 1 day | 16 |
| Effect of Varying Molecular Weight of Oat β-Glucan Taken just before Eating on Postprandial Glycemic Response in Healthy Humans 2020 · MW4 · Healthy adults; 16 participants, 9 men and 7 non-pregnant women, mean age 41 years | 4 g | 1 day | 16 |
| Effect of Varying Molecular Weight of Oat β-Glucan Taken just before Eating on Postprandial Glycemic Response in Healthy Humans 2020 · OP1 · Healthy adults; 16 participants, 9 men and 7 non-pregnant women, mean age 41 years | 4 g | 1 day | 16 |
| Effect of Varying Molecular Weight of Oat β-Glucan Taken just before Eating on Postprandial Glycemic Response in Healthy Humans 2020 · OP2 · Healthy adults; 16 participants, 9 men and 7 non-pregnant women, mean age 41 years | 4 g | 1 day | 16 |
| Effect of beta glucan on white blood cell counts and serum levels of IL-4 and IL-12 in women with breast cancer undergoing chemotherapy: a randomized double-blind placebo-controlled clinical trial 2014 · intervention group · Women aged 28–65 years with breast carcinoma undergoing chemotherapy | 20 mg | 3 weeks | 15 |
| Extracted oat and barley β-glucans do not affect cholesterol metabolism in young healthy adults 2013 · oat β-glucan · young healthy adults | 3.3 g | 3 weeks | 14 |
| Extracted oat and barley β-glucans do not affect cholesterol metabolism in young healthy adults 2013 · barley β-glucan · young healthy adults | 3.3 g | 3 weeks | 14 |
| Extracted oat and barley β-glucans do not affect cholesterol metabolism in young healthy adults 2013 · barley mutant β-glucan · young healthy adults | 3.3 g | 3 weeks | 14 |
| Muesli with 4 g oat beta-glucans lowers glucose and insulin responses after a bread meal in healthy subjects 2008 · Muesli with 4 g beta-glucans (series 2) · Healthy volunteers with normal body mass index | 4 g | 1 day | 13 |
| Glycemic effect of oat and barley beta-glucan when incorporated into a snack bar: a dose escalation study 2014 · 1.5 g oat β-glucan snack bar · Healthy males and females | 1.5 g | 1 day | 12 |
| Glycemic effect of oat and barley beta-glucan when incorporated into a snack bar: a dose escalation study 2014 · 3 g oat β-glucan snack bar · Healthy males and females | 3 g | 1 day | 12 |
| Glycemic effect of oat and barley beta-glucan when incorporated into a snack bar: a dose escalation study 2014 · 6 g oat β-glucan snack bar · Healthy males and females | 6 g | 1 day | 12 |
| Glycemic effect of oat and barley beta-glucan when incorporated into a snack bar: a dose escalation study 2014 · 1.5 g barley β-glucan snack bar · Healthy males and females | 1.5 g | 1 day | 12 |
| Glycemic effect of oat and barley beta-glucan when incorporated into a snack bar: a dose escalation study 2014 · 3 g barley β-glucan snack bar · Healthy males and females | 3 g | 1 day | 12 |
| Glycemic effect of oat and barley beta-glucan when incorporated into a snack bar: a dose escalation study 2014 · 6 g barley β-glucan snack bar · Healthy males and females | 6 g | 1 day | 12 |
| Effect of Pleuran (β-glucan from Pleurotus ostreatus) supplementation on cellular immune response after intensive exercise in elite athletes 2010 · β-glucan group · Elite athletes undergoing intensive training; age and sex not stated | 100 mg | 60 days | 9 |
| Oat beta-glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol excretion in ileostomy subjects 1995 · OB diet · Nine ileostomy subjects; age and sex not reported | 12.5 g | 2 days | 9 |
| Oat beta-glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol excretion in ileostomy subjects 1995 · OBE diet · Nine ileostomy subjects; age and sex not reported | 3.8 g | 2 days | 9 |
| Oat beta-glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol excretion in ileostomy subjects 1995 · B diet · Nine ileostomy subjects; age and sex not reported | 13 g | 2 days | 9 |
| Oat beta-glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol excretion in ileostomy subjects 1995 · W diet · Nine ileostomy subjects; age and sex not reported | 1.2 g | 2 days | 9 |
| Oat bran stimulates bile acid synthesis within 8 h as measured by 7alpha-hydroxy-4-cholesten-3-one 2002 · oat bran · 8 subjects; age, sex, and health condition not reported | 11 g | 3 days | 8 |
| Cholesterol-lowering benefits of oat-containing cereal in Hispanic americans 2005 · oat cereal · Men and women aged 30–70 years with baseline LDL-C levels of 120–190 mg/dL and triglycerides <400 mg/dL | 3 g | 6 weeks | — |
| Changes in serum lipids and postprandial glucose and insulin concentrations after consumption of beverages with beta-glucans from oats or barley: a randomised dose-controlled trial 2005 · 5 g beta-glucans from oats · Free-living adults with hypercholesterolaemia; age and sex not specified | 5 g | 5 weeks | — |
| Changes in serum lipids and postprandial glucose and insulin concentrations after consumption of beverages with beta-glucans from oats or barley: a randomised dose-controlled trial 2005 · 10 g beta-glucans from oats · Free-living adults with hypercholesterolaemia; age and sex not specified | 10 g | 5 weeks | — |
| Changes in serum lipids and postprandial glucose and insulin concentrations after consumption of beverages with beta-glucans from oats or barley: a randomised dose-controlled trial 2005 · 5 g beta-glucans from barley · Free-living adults with hypercholesterolaemia; age and sex not specified | 5 g | 5 weeks | — |
| Changes in serum lipids and postprandial glucose and insulin concentrations after consumption of beverages with beta-glucans from oats or barley: a randomised dose-controlled trial 2005 · 10 g beta-glucans from barley · Free-living adults with hypercholesterolaemia; age and sex not specified | 10 g | 5 weeks | — |
| Effect of high beta-glucan barley on serum cholesterol concentrations and visceral fat area in Japanese men--a randomized, double-blinded, placebo-controlled trial 2008 · test group · Hypercholesterolemic Japanese men with BMI >22 kg/m² | 7 g | 12 weeks | — |
| Physiological effects of concentrated barley beta-glucan in mildly hypercholesterolemic adults 2008 · low molecular weight (low-MW) concentrated barley beta-glucan · Hypercholesterolemic men and women; ages not reported | 6 g | 6 weeks | — |
| Physiological effects of concentrated barley beta-glucan in mildly hypercholesterolemic adults 2008 · high molecular weight (high-MW) concentrated barley beta-glucan · Hypercholesterolemic men and women; ages not reported | 6 g | 6 weeks | — |
| A controlled study of consumption of beta-glucan-enriched soups for 2 months by type 2 diabetic free-living subjects 2010 · beta-glucan soup · Adults with type 2 diabetes; age range and sex not specified | 3.5 g | 8 weeks | — |
| Impact of beta-glucan on the faecal microbiota of polypectomized patients: a pilot study 2011 · β-glucan group · Men and women with a history of colorectal polyps who had undergone polypectomy; mean age 57.6 years | 3 g | 90 days | — |
| Effect of 6 weeks' consumption of β-glucan-rich oat products on cholesterol levels in mildly hypercholesterolaemic overweight adults 2012 · low-dose oat β-glucan (oats low - OL) · Mildly hypercholesterolaemic overweight men and women; ages not reported | 1.5 g | 6 weeks | — |
| Effect of 6 weeks' consumption of β-glucan-rich oat products on cholesterol levels in mildly hypercholesterolaemic overweight adults 2012 · higher-dose oat β-glucan (oats high - OH) · Mildly hypercholesterolaemic overweight men and women; ages not reported | 3 g | 6 weeks | — |
| Supplementation with a soluble β-glucan exported from Shiitake medicinal mushroom, Lentinus edodes (Berk.) singer mycelium: a crossover, placebo-controlled study in healthy elderly 2011 · Lentinex · Healthy elderly subjects | 2.5 mg | 6 weeks | — |
| High-Molecular-Weight β-Glucan Decreases Serum Cholesterol Differentially Based on the CYP7A1 rs3808607 Polymorphism in Mildly Hypercholesterolemic Adults 2016 · 3 g high-MW β-glucan/d · Adults aged 27–78 years, men and women, with mild hypercholesterolemia | 3 g | 5 weeks | — |
| High-Molecular-Weight β-Glucan Decreases Serum Cholesterol Differentially Based on the CYP7A1 rs3808607 Polymorphism in Mildly Hypercholesterolemic Adults 2016 · 5 g low-MW β-glucan/d · Adults aged 27–78 years, men and women, with mild hypercholesterolemia | 5 g | 5 weeks | — |
| High-Molecular-Weight β-Glucan Decreases Serum Cholesterol Differentially Based on the CYP7A1 rs3808607 Polymorphism in Mildly Hypercholesterolemic Adults 2016 · 3 g low-MW β-glucan/d · Adults aged 27–78 years, men and women, with mild hypercholesterolemia | 3 g | 5 weeks | — |
| Barley β-glucan reduces blood cholesterol levels via interrupting bile acid metabolism 2017 · 3 g HMW barley β-glucan · Participants with mild hypercholesterolaemia | 3 g | 5 weeks | — |
| Alterations in gut microbiota composition and metabolic parameters after dietary intervention with barley beta glucans in patients with high risk for metabolic syndrome development 2019 · test group · Volunteers at high risk for metabolic syndrome development or with diagnosed metabolic syndrome; age and sex not specified | 6 g | 4 weeks | — |
| Consumption of a meal containing refined barley flour bread is associated with a lower postprandial blood glucose concentration after a second meal compared with one containing refined wheat flour bread in healthy Japanese: A randomized control trial 2020 · Refined barley flour bread · Healthy young Japanese adults | 2.5 g | 1 day | — |
| High β-Glucan Whole Grain Barley Reduces Postprandial Glycemic Response in Healthy Adults-Part One of a Randomized Controlled Trial 2025 · Low β-glucan barley, unsweetened (LB) · Healthy men and women aged 18–50 years with normal fasting blood glucose | 4.2 g | 1 day | — |
| High β-Glucan Whole Grain Barley Reduces Postprandial Glycemic Response in Healthy Adults-Part One of a Randomized Controlled Trial 2025 · Medium β-glucan barley, unsweetened (MB) · Healthy men and women aged 18–50 years with normal fasting blood glucose | 4.8 g | 1 day | — |
| High β-Glucan Whole Grain Barley Reduces Postprandial Glycemic Response in Healthy Adults-Part One of a Randomized Controlled Trial 2025 · High β-glucan barley, unsweetened (HB) · Healthy men and women aged 18–50 years with normal fasting blood glucose | 5.7 g | 1 day | — |
| High β-Glucan Whole Grain Barley Reduces Postprandial Glycemic Response in Healthy Adults-Part One of a Randomized Controlled Trial 2025 · Low β-glucan barley with HFCS (LB + 50 g HFCS) · Healthy men and women aged 18–50 years with normal fasting blood glucose | 4.2 g | 1 day | — |
| High β-Glucan Whole Grain Barley Reduces Postprandial Glycemic Response in Healthy Adults-Part One of a Randomized Controlled Trial 2025 · Medium β-glucan barley with HFCS (MB + 50 g HFCS) · Healthy men and women aged 18–50 years with normal fasting blood glucose | 4.8 g | 1 day | — |
| High β-Glucan Whole Grain Barley Reduces Postprandial Glycemic Response in Healthy Adults-Part One of a Randomized Controlled Trial 2025 · High β-glucan barley with HFCS (HB + 50 g HFCS) · Healthy men and women aged 18–50 years with normal fasting blood glucose | 5.7 g | 1 day | — |
| Yeast Beta-Glucan Enhances Antibody Response Following Influenza Vaccination - A Double-Blind, Randomized, Placebo-Controlled Pilot Trial 2025 · beta-glucan group · Adults, mean age 70.7 ± 10.1 years, receiving influenza vaccination | 500 mg | — | — |
| High molecular weight oat β-glucan enhances lipid-lowering effects of phytosterols. A randomised controlled trial 2020 · PS-OBG · Hypercholesterolaemic individuals; age and sex not stated | 3 g | 6 weeks | 18 |
| Benefits of Gut Microbiota Reconstitution by Beta 1,3-1,6 Glucans in Subjects with Autism Spectrum Disorder and Other Neurodegenerative Diseases 2023 · Arm 2 or Group 2 (Nichi Glucan group) · Children aged 3–18 years, male and female, with autism spectrum disorder | 1 g | 90 days | 11 |
| Oat bran rapidly increases bile acid excretion and bile acid synthesis: an ileostomy study 2007 · native beta-glucans · Nine volunteers with conventional ileostomies | 11.6 g | 3 days | 9 |
| Oat bran rapidly increases bile acid excretion and bile acid synthesis: an ileostomy study 2007 · hydrolysed beta-glucans · Nine volunteers with conventional ileostomies | 11.6 g | 3 days | 9 |
| Effect of combination of Beta Glucan and Lactobacillus rhamnosus HerizI on white blood cell counts and serum levels of IL-4 and IL-12 in women with breast cancer undergoing chemotherapy: A randomized double-blind placebo-controlled clinical trial 2024 · intervention group · Women with breast cancer receiving chemotherapy | 20 mg | 3 weeks | — |
| GLP-1 Responses to a Single Meal Fortified With Oyster Mushroom Powder in Adults With Impaired Glucose Tolerance Depend on the Gut Microbiota Composition Before the Meal 2025 · Enriched meal (EN) · Adults with impaired glucose tolerance; ages and sex by arm not reported | 8.1 g | 1 day | — |
| Effect and Tolerability of a Nutritional Supplement Based on a Synergistic Combination of β-Glucans and Selenium- and Zinc-Enriched Saccharomyces cerevisiae (ABB C1(®)) in Volunteers Receiving the Influenza or the COVID-19 Vaccine: A Randomized, Double-Blind, Placebo-Controlled Study 2021 · ABB C1® group, COVID-19-vaccine cohort · Men and women aged 18 years or older receiving COVID-19 vaccine, recruited from long-stay centers or as healthcare workers at the study centers | 517 mg | 5 weeks | 18 |
| Effects of baked products enriched with n-3 fatty acids, folates, β-glucans, and tocopherol in patients with mild mixed hyperlipidemia 2012 · active diet · Adults with mild plasma lipid abnormalities (mild mixed hyperlipidemia) | 3.6 g | 30 days | 16 |
| Gastrointestinal microbiome modulator improves glucose tolerance in overweight and obese subjects: A randomized controlled pilot trial 2015 · GIMM · Adults aged 18–70 who were overweight or obese (BMI 25–45 kg/m²) and had fasting blood glucose of 100–200 mg/dL | 2.5 g | 4 weeks | 15 |
| Effect and Tolerability of a Nutritional Supplement Based on a Synergistic Combination of β-Glucans and Selenium- and Zinc-Enriched Saccharomyces cerevisiae (ABB C1(®)) in Volunteers Receiving the Influenza or the COVID-19 Vaccine: A Randomized, Double-Blind, Placebo-Controlled Study 2021 · ABB C1® group, influenza-vaccine cohort · Men and women aged 60 years or older receiving influenza vaccine and requiring hospitalization or ambulatory follow-up by palliative support teams | 517 mg | 30 days | 14 |
| Evaluation of novel nutraceuticals based on the combination of oat beta-glucans and a green coffee phenolic extract to combat obesity and its comorbidities. A randomized, dose-response, parallel trial 2022 · 3 g/day, 35% beta-glucans group · Overweight or obese subjects; age and sex not stated | 3 g | 6 weeks | 15 |
| Evaluation of novel nutraceuticals based on the combination of oat beta-glucans and a green coffee phenolic extract to combat obesity and its comorbidities. A randomized, dose-response, parallel trial 2022 · 3 g/day, 70% beta-glucans group · Overweight or obese subjects; age and sex not stated | 3 g | 6 weeks | 15 |
| Evaluation of novel nutraceuticals based on the combination of oat beta-glucans and a green coffee phenolic extract to combat obesity and its comorbidities. A randomized, dose-response, parallel trial 2022 · 5 g/day, 35% beta-glucans group · Overweight or obese subjects; age and sex not stated | 5 g | 6 weeks | 15 |
| Evaluation of novel nutraceuticals based on the combination of oat beta-glucans and a green coffee phenolic extract to combat obesity and its comorbidities. A randomized, dose-response, parallel trial 2022 · 5 g/day, 70% beta-glucans group · Overweight or obese subjects; age and sex not stated | 5 g | 6 weeks | 15 |
| Barley β-glucan reduces blood cholesterol levels via interrupting bile acid metabolism 2017 · 5 g LMW barley β-glucan · Participants with mild hypercholesterolaemia | 5 g | 5 weeks | — |
| Barley β-glucan reduces blood cholesterol levels via interrupting bile acid metabolism 2017 · 3 g LMW barley β-glucan · Participants with mild hypercholesterolaemia | 3 g | 5 weeks | — |